Mobocertinib (TAK-788) as a monotherapy is in clinical developmentfor the treatment oflocallyadvanced or metastatic non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. In locally advanced or metastaticNSCLC(StageIIIB orIV),the cancer has spread beyond the lung which was initially affected. Symptoms of lung cancer include a persistent cough, shortness of breath, coughing up blood, aches and pains in the chest or shoulder, loss of appetite, weight loss and fatigue. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. Advanced NSCLC is not usually curable; there is therefore the need for additional treatment options.
Mobocertinibis an oral drug that targets the proteinsEGFRhuman epidermal growth factor receptor 2 (HER2).Itcan bind to particularmutant forms of EGFR,includingEGFR Exon 20 insertion mutations,toinhibit the growth of tumour cells.If licenced,mobocertinib monotherapy would offer a treatment option for patients with locally advanced or metastatic NSCLC.